两融数据显示，该股最新融资余额为13.95亿元，近5日减少3339.46万元，降幅为2.34%。 特宝生物12月17日大宗交易平台出现一笔成交，成交量3.24万股，成交金额270.67万元，大宗交易成交 价为83.54元。该笔交易的买方营业部为国泰海通证券股份有限公司总部，卖方营业部为广发证券股份 有限公司厦门湖滨南路证券营业部。 进一步统计，近3个月内该股累计发生9笔大宗交易，合计成交金额为6873.58万元。 证券时报·数据宝统计显示，特宝生物今日收盘价为83.54元，上涨0.29%，日换手率为0.31%，成交额为 1.06亿元，全天主力资金净流出848.53万元，近5日该股累计平盘报收，近5日资金合计净流出7451.72万 元。 据天眼查APP显示，厦门特宝生物工程股份有限公司成立于1996年08月07日，注册资本40818.948万人 民币。（数据宝） 12月17日特宝生物大宗交易一览 | 成交量 | 成交金额 | 成交价格 | 相对当日收盘折 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | | （万股） | （万元） | （元） | 溢 ...

Investment Rating - The report maintains an "Outperform" rating for several companies in the innovative drug and medical device industry, including Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical Group, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical [5][6][25]. Core Insights - The report emphasizes the high prosperity in innovative drugs and continues to recommend companies with innovative pipelines that are entering a volume increase phase, maintaining "Outperform" ratings for various Biopharma/Biotech companies [5][25]. - The National Healthcare Security Administration announced the 2025 insurance drug list, which added 114 drugs, including 50 innovative drugs, further validating insurance support for innovation and indicating promising domestic demand [26][27]. Summary by Sections 1. Continuous Recommendation of Innovative Drugs and Industry Chain - The report highlights the ongoing recommendation of innovative drugs and the industry chain, with a focus on companies expected to see a revaluation due to their innovative pipelines [5][25]. - Specific companies mentioned include WuXi AppTec, WuXi XDC Cayman, Hangzhou Tigermed Consulting, and leading medical equipment companies like Beijing Chunlizhengda Medical Instruments and Lepu Medical, all rated "Outperform" [5][25]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of December 2025, the A-Shares pharmaceutical sector underperformed the market, with the SW Pharma and Biotech index falling by 1.0% compared to a 0.3% decline in the SHCOMP [8][27]. - The report notes that the premium level of the pharmaceutical sector relative to all A-Shares is at a normal level, with a current relative premium rate of 69.8% [16][27]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong stock pharmaceutical sector underperformed the market, with the Hang Seng Healthcare index falling by 2.3%, while the U.S. stock pharmaceutical sector outperformed, with the S&P 500 Healthcare Select Sector Index rising by 0.4% [28][27].

Investment Rating - The report maintains an "Overweight" rating for the innovative pharmaceutical and medical device industry chain [3][5][6]. Core Insights - The report emphasizes the continuous recommendation of innovative drugs and medical devices, highlighting the high growth potential in the innovative pharmaceutical sector. It maintains "Overweight" ratings for companies such as Heng Rui Medicine, Hansoh Pharmaceutical, and others, indicating a potential for value re-evaluation [3][5]. - The report notes that the National Medical Insurance Administration has officially announced the 2025 medical insurance drug catalog, which includes 114 new drugs, 50 of which are first-class innovative drugs. This adjustment is seen as a validation of the support for innovation in the healthcare sector [3][5]. - The A-share pharmaceutical sector underperformed the broader market in the second week of December 2025, with the SW Pharmaceutical Biotechnology index declining by 1.0% compared to a 0.3% drop in the Shanghai Composite Index [7][18]. Summary by Sections Section 1: Continuous Recommendation of Innovative Drugs and Medical Devices - The report highlights the sustained recommendation of innovative drugs and medical devices, with a focus on companies that are expected to see performance growth and value re-evaluation [5][6]. Section 2: A-share Pharmaceutical Sector Performance - In the second week of December 2025, the A-share pharmaceutical sector's performance was weaker than the overall market, ranking 16th among the primary industries [7][18]. Section 3: Hong Kong and US Market Performance - The report indicates that the Hong Kong pharmaceutical sector also underperformed, while the US pharmaceutical sector showed stronger performance compared to the broader market [18].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会 会议资料 （688278） 中国·厦门 厦门特宝生物工程股份有限公司 2025 年第一次临时股东大会会议资料 会议须知 为保障厦门特宝生物工程股份有限公司（以下简称"公司"）全体股东 的合法权益，维护股东大会的正常秩序，确保本次股东大会顺利召开，根据 《公司章程》《股东大会议事规则》及有关法律法规的规定，特制定本须知， 望出席股东大会的全体人员遵照执行。 一、本公司董事会办公室具体负责会议的程序安排和会务工作。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东及股东 代理人的合法权益，除出席会议的股东及股东代理人、公司董事、监事、高 级管理人员、公司聘请的律师及董事会邀请的人员外，公司有权依法拒绝其 他人员进入会场。 三、为保障本次股东大会的顺利召开，股东及股东代理人须在会议召 开前 30 分钟到会议现场办理签到手续，并按规定出示证券账户卡、身份证 明文件或企业营业执照/注册证书复印件（加盖公章）、授权委托书等，经 验证后方可出席会议。 四、本次股东大会采取现场投票和网络投票相结合的方式表决，结合 现场投票和网络投票的表决结果发布股东大会决议 ...

（来源：淘金ETF） 1. 瑞芯微（603893） 扎根福建福州的本土芯片设计企业，深耕半导体领域多年，是国内少有的具备完整SoC芯片研发能力的 企业，核心技术团队拥有十余年行业经验，在国产芯片替代浪潮中占据重要地位。核心业务：专注于 AIoT（人工智能物联网）系统级芯片研发、设计与销售，产品线覆盖旗舰AIoT SoC、端侧AI协处理 器、视觉处理芯片三大核心系列，可满足不同场景下的高算力需求。热点概念：叠加端侧AI、机器 人、智能座舱、华为鸿蒙生态四大核心热点，其RK3588系列芯片已批量应用于工业巡检机器人、AGV 设备及中高端智能座舱方案，还是开源鸿蒙标准系统硬件使用率最高的芯片厂商。政策利好预期：受益 于福建"十五五"规划中数字经济与半导体产业扶持政策，以及自贸区集成电路产业税收优惠、研发补贴 等政策，同时国产芯片自主可控战略下，企业有望获得更多省级专项扶持资金，助力其在机器人、汽车 电子等新兴赛道的布局深化。 2. 亿联网络（300628） 总部位于厦门的全球领先沟通与协作解决方案提供商，以自主创新为核心，拥有多项音视频核心技术专 利，产品畅销全球140多个国家和地区，是福建自贸区外向型科技企业的典 ...

本报讯(记者李婷)近日，国家医疗保障局、人力资源社会保障部联合公布《国家基本医疗保险、工伤保 险和生育保险药品目录(2025年版)》，厦门特宝生物工程股份有限公司(以下简称"特宝生物")自主研发 的国家1类新药益佩生(通用名：怡培生长激素注射液)成功纳入该目录，将于2026年1月1日正式实施， 此举将有效提升药物可及性，降低患者用药负担，惠及更广泛的矮小症患者群体。 在创新研发领域，特宝生物长期聚焦长效蛋白质药物研发，尤其在聚乙二醇修饰技术领域优势显著。经 过近30年技术积累，公司已构建起以"聚乙二醇长效化药物"为核心的创新平台，依托该平台已上市多款 聚乙二醇长效化国家1类新药，成长为国内聚乙二醇长效蛋白质领域的领军企业。研发投入上，2025年 前三季度公司研发投入达3.12亿元，同比增长38.53%，为持续创新提供强劲支撑；同时公司还推动多平 台技术协同创新，已建立聚乙二醇重组蛋白质修饰、蛋白质药物生产、药物筛选及优化三大核心技术平 台，并在核酸药物、腺相关病毒(AAV)基因治疗等领域形成技术积累。 特宝生物表示，未来将持续加大研发创新力度，推出更多高质量、可及性强的创新治疗方案，助力儿童 生长发育领域规范 ...

12月9日，A股市场震荡回调，创新药板块冲高回落。截至10:31，20CM涨跌幅的科创创新药ETF汇添富（589120）走平，早盘一度涨超1%！资金小跑进 场，科创创新药ETF汇添富（589120）近5日中有3日吸金，近5日合计净流入超939万元！ 科创创新药ETF汇添富（589120）标的指数成分股涨跌不一，艾力斯、百利天恒等涨超1%，百济神州等微涨，迈威生物等跌超2%，荣昌生物、泽璟制药等 回调。 截至10:33，成分股仅做展示使用，不构成投资建议。 消息面上，2025年国家基本医疗保险、生育保险和工伤保险药品目录是国家医保局成立以来的第8次调整。本次目录调整新增114种药品，其中50种为1类创 新药。首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有社会关注度较高的阿尔茨海默病治疗药品。 【基本医保目录以及首版商保目录发布，延续支持创新！】 招银国际火线点评，2025年版基本医保目录以及首版商保目录发布，延续支持创新。本次目录调整新增114种药品，其中50种1类创新药，同时调出了29种临 床没有供应或可被其他药物更好替代的药品。本次调整在坚持"保基本""尽力而为、量力而行"的基础上， ...

在乙肝领域，特宝生物支持的"珠峰项目"为无数患者带来了临床治愈的希望；在儿科领域，益佩生®同 样承载着这样的使命——让更多矮小症患儿不仅能"用得起"长效生长激素，更能"用得好、用得安全"。 此次益佩生®纳入医保，将显著提升药物的可及性，降低患者家庭经济负担，让高品质创新药"飞入寻 常百姓家"。而企业对高标准、无防腐剂等生产工艺的坚守，则确保了药品在可及性提升的同时，始终 保持安全可靠的品质和疗效。这种"可及性"与"高质量"的统一，正是特宝生物"以患者为中心"承诺的最 佳注脚。 展望2026年，随着新版医保目录的落地执行，益佩生®有望继派格宾®之后，成为驱动特宝生物业绩增 长的第二引擎。而对于资本市场而言，一家始终将技术创新聚焦于解决实际临床问题的公司，其长期成 长逻辑已然清晰可见。 此次进入医保，对于特宝生物而言意义深远，不仅标志着产品获得国家级市场准入资格，更在医保谈 判"保基本"的大背景下，验证了一个核心商业命题：具备显著临床优势和更高安全性的差异化创新药， 才能获得认可与支持。 益佩生®能够顺利入局，得益于其扎实的"品质硬实力"，尤其是其在分子设计层面的突破性创新和安全 性升级，为产品构建了难以复制的差 ...

益佩生®能够顺利入局，得益于其扎实的"品质硬实力"，尤其是其在分子设计层面的突破性创新和安全 性升级，为产品构建了难以复制的差异化优势。在儿科用药领域，能通过技术手段实现更高的"安全 性"，本身就是极具价值的创新，特宝生物通过研发创新攻克了这一难题，这也表明只有真正解决临床 痛点的产品，才能获得长足发展。 特宝生物在长效蛋白质药物领域深耕多年，其核心竞争力在于能够驾驭高壁垒的生物工程技术，并将其 精准转化为直击用户痛点的临床获益。回顾企业的发展历程，从深耕乙肝临床治愈的"派格宾®"，到如 今呵护儿童成长的"益佩生®"，特宝生物始终在践行一种朴素的价值观：坚持做难而正确的事。 中证报中证网讯（王珞）12月7日，特宝生物自主研发的长效生长激素——怡培生长激素注射液（商品 名：益佩生®）成功通过谈判纳入医保目录。 此次进入医保，对于特宝生物而言意义深远，不仅标志着产品获得国家级市场准入资格，更在医保谈 判"保基本"的大背景下，验证了一个核心商业命题：具备显著临床优势和更高安全性的差异化创新药， 才能获得认可与支持。 此次益佩生®纳入医保，将显著提升药物的可及性，降低患者家庭经济负担，让高品质创新药"飞入寻 常百姓家 ...